 03 PM / Updated 11 minutes ago BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda Reuters Staff 1 Min Read 
Jan 9 (Reuters) - Eisai Co Ltd: 
* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA速 (LENVATINIB MESYLATE) AND KEYTRUDA速 (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA 
* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA速 (LENVATINIB MESYLATE) AND KEYTRUDA速 (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: